Pluri Inc. (PLUR)

NASDAQ: PLUR · IEX Real-Time Price · USD
5.25
-0.51 (-8.85%)
Apr 17, 2024, 1:57 PM EDT - Market open
-8.85%
Market Cap 26.78M
Revenue (ttm) 357,000
Net Income (ttm) -23.95M
Shares Out 5.19M
EPS (ttm) -4.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 54,736
Open 5.46
Previous Close 5.76
Day's Range 4.71 - 5.48
52-Week Range 3.44 - 8.56
Beta 1.51
Analysts n/a
Price Target n/a
Earnings Date May 7, 2024

About PLUR

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta tha... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 123
Stock Exchange NASDAQ
Ticker Symbol PLUR
Full Company Profile

Financial Performance

In 2023, Pluri's revenue was $287,000, an increase of 22.65% compared to the previous year's $234,000. Losses were -$28.32 million, -31.33% less than in 2022.

Financial Statements

News

Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method

HAIFA, Israel, April 08, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company, Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) (“Pluri” or the “Company”), which transforms cells into solutions that promote glo...

9 days ago - GlobeNewsWire

Pluri's Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences

Pluri's business verticals leverage Company's world-leading 3D cell expansion know-how, IP, and manufacturing facility to drive revenue and bring innovative cell-based solutions to numerous industries...

20 days ago - GlobeNewsWire

Pluri Inc. Announces 1-for-8 Reverse Share Split

HAIFA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) ("Pluri" or the “Company"), a leading biotechnology company that transforms cells into solutions, today announc...

21 days ago - GlobeNewsWire

Pluri's Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report

HAIFA, Israel, March 21, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions that promote glo...

27 days ago - GlobeNewsWire

Engage with Pluri's Talent: Exciting Conference Appearances Ahead

HAIFA, Israel, March 19, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions that promote glo...

4 weeks ago - GlobeNewsWire

Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing

PluriCDMO™ will support Remedy Cell in the manufacture of RC-0315 product candidate for the treatment of Idiopathic Pulmonary Fibrosis (IPF) PluriCDMO™ will support Remedy Cell in the manufacture of R...

4 weeks ago - GlobeNewsWire

Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation

Patent helps position Pluri as a leader in cell expansion for the agtech industry with the launch of its PluriAgtech business vertical and cell-based coffee product Patent helps position Pluri as a le...

5 weeks ago - GlobeNewsWire

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote global ...

6 weeks ago - GlobeNewsWire

Pluri's Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals

HAIFA, Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) (“Pluri” or the “Company”) today issued the following update from CEO and President,...

7 weeks ago - GlobeNewsWire

Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis

HAIFA, Israel, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote global w...

3 months ago - GlobeNewsWire

Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization

Pluri, an established global leader in the development and manufacturing of cell-based therapeutics, launches new revenue-generating Contract Development and Manufacturing Organization (CDMO) division...

3 months ago - GlobeNewsWire

Pluri's PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation

HAIFA, Israel, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote wellbein...

8 months ago - GlobeNewsWire

Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors

Abony: “Pluri's cell expansion technology has extraordinary potential across a range of industries.” Abony: “Pluri's cell expansion technology has extraordinary potential across a range of industries....

9 months ago - GlobeNewsWire

U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri's PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome

HAIFA, Israel, July 11, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote wellbein...

10 months ago - GlobeNewsWire

Cell Manufacturing Pioneer, Pluri Inc., Unveils PluriMatrix: a Breakthrough System for Unprecedented Industrial Scale Production of Cell-Based Products

HAIFA, Israel, April 27, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote wellbei...

1 year ago - GlobeNewsWire

Israel's Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender Diversity and Pay Equity

HAIFA, Israel, March 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, a...

1 year ago - GlobeNewsWire

Pluri CEO Issues Letter to Shareholders Summarizing the Strategy Change and Progress in 2022 and Announcing Food Tech Joint Venture Proof of Concept

HAIFA, Israel, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology Company, to...

1 year ago - GlobeNewsWire

Pluri Prices $8.2 million Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

HAIFA, Israel, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company, announced today that it has signed securities purch...

1 year ago - GlobeNewsWire

Pluri wins BioTech Breakthrough Cell Innovation of the Year Award

HAIFA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company” (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, won...

1 year ago - GlobeNewsWire

Pluri to Present and Participate in Upcoming Conferences

HAIFA, Israel, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”)(formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, tod...

1 year ago - GlobeNewsWire

Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates

HAIFA, Israel, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, t...

1 year ago - GlobeNewsWire

€7.5 Million Granted to Collaborative PROTO Project led by Charité to Study Pluri's PLX-PAD Cells for Osteoarthritis Treatment

HAIFA, Israel, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, t...

1 year ago - GlobeNewsWire

Pluri CEO Issues Shareholder Update

HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, to...

1 year ago - GlobeNewsWire

Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries

HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company, today announced its name change (from Pluristem The...

1 year ago - GlobeNewsWire

Pluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgery

Pluristem Therapeutics Inc (NASDAQ: PSTI) announced topline results from its Phase 3 study of intramuscular administration of allogeneic PLX-PAD cells for muscle injury following arthroplasty for hip ...

1 year ago - Benzinga